Weng Tao
About
In The Last Decade
Weng Tao
34 papers receiving 2.2k citations
Peers
Comparison fields: 5 of 90
- Molecular Biology 1.7k
- Ophthalmology 1.1k
- Radiology, Nuclear Medicine and Imaging 715
- Cellular and Molecular Neuroscience 663
- Genetics 164
Countries citing papers authored by Weng Tao
This map shows the geographic impact of Weng Tao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weng Tao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weng Tao more than expected).
Fields of papers citing papers by Weng Tao
This network shows the impact of papers produced by Weng Tao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weng Tao. The network helps show where Weng Tao may publish in the future.
Co-authorship network of co-authors of Weng Tao
This figure shows the co-authorship network connecting the top 25 collaborators of Weng Tao. A scholar is included among the top collaborators of Weng Tao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weng Tao. Weng Tao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 2 | |
| 3 | 0 | |
| 4 | 78 | |
| 5 | 1 | |
| 6 | 61 | |
| 7 | Intraocular Delivery of Ciliary Neurotrophic Factor (CNTF) by Encapsulated Cell Technology Implants Restores Cone Function and Day Vision in Dogs with CNGB3-Achromatopsia | 1 |
| 8 | Safety of implantation of the NT-503 device in patients with Choroidal Neovascularization secondary to Age-related Macular Degeneration | 7 |
| 9 | Continuous Intraocular Drug Delivery over 5 ½ Years: Ciliary Neurotrophic Factor (CNTF)Production by Encapsulated Cell Technology Implants Treating Patients with Retinitis Pigmentosa and Geographic Atrophy | 2 |
| 10 | 152 | |
| 11 | Long-Term, Sustained Intraocular Delivery of a VEGF Antagonist Using Encapsulated Cell Technology Implant for the Treatment of Choroidal Neovascular Diseases | 1 |
| 12 | 139 | |
| 13 | A Phase 2 Study of Encapsulated CNTF-Secreting Cell Implant (NT-501) In Patients with Geographic Atrophy Associated with Dry AMD | 3 |
| 14 | 170 | |
| 15 | 12 | |
| 16 | 99 | |
| 17 | 78 | |
| 18 | 14 | |
| 19 | 44 | |
| 20 | 16 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.